menu
    • menu
    [{"orgOrder":0,"company":"Egis Pharmaceuticals PLC","sponsor":"Crescita Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Egis Pharmaceuticals PLC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Egis Pharmaceuticals PLC \/ Egis Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Egis Pharmaceuticals PLC \/ Egis Pharmaceuticals"},{"orgOrder":0,"company":"Egis Pharmaceuticals PLC","sponsor":"National Institute of Pharmacy and Nutrition","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HUNGARY","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Egis Pharmaceuticals PLC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Egis Pharmaceuticals PLC \/ National Institute of Pharmacy and Nutrition","highestDevelopmentStatusID":"12","companyTruncated":"Egis Pharmaceuticals PLC \/ National Institute of Pharmacy and Nutrition"}]

    Find Clinical Drug Pipeline Developments & Deals by Egis Pharmaceuticals PLC

    Menu

    Egis Pharmaceuticals PLC

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    Key Products KEY PRODUCTS

    SERVICES

    Key Services KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Egis Pharmaceuticals PLC

                            Hungary
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

                            Lead Product(s) : Lidocaine,Tetracaine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Crescita Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Crescita Signs Exclusive 8-Country Licensing Agreement with Egis Pharmaceuticals for Pliaglis®

                            Details : The formulation contains a eutectic mixture of 7% lidocaine and 7% tetracaine that utilizes phase-changing topical cream Peel technology. In clinical studies, the mean duration of anesthesia has been shown to be in the range of 7 to 9 hours after the app...

                            Brand Name : Pliaglis

                            Molecule Type : Small molecule

                            Upfront Cash : $0.7 million

                            December 13, 2021

                            Lead Product(s) : Lidocaine,Tetracaine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Crescita Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            Egis Pharmaceuticals

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Egis Pharmaceuticals PLC

                            Hungary
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

                            Lead Product(s) : Favipiravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : National Institute of Pharmacy and Nutrition

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Egis Favipiravir Drug Licenced for Covid-19 Treatment

                            Details : The active ingredient favipiravir manufactured by Hungarian pharmaceutical company Egis has been licenced for treatment of Covid-19 by the National Institute of Pharmacy and Nutrition (OGYÉI).

                            Brand Name : Favipiravir-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 20, 2020

                            Lead Product(s) : Favipiravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : National Institute of Pharmacy and Nutrition

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Egis Pharmaceuticals

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth